JP2022517407A5 - - Google Patents

Info

Publication number
JP2022517407A5
JP2022517407A5 JP2021541198A JP2021541198A JP2022517407A5 JP 2022517407 A5 JP2022517407 A5 JP 2022517407A5 JP 2021541198 A JP2021541198 A JP 2021541198A JP 2021541198 A JP2021541198 A JP 2021541198A JP 2022517407 A5 JP2022517407 A5 JP 2022517407A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
aav vector
composition according
use according
monogenotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021541198A
Other languages
English (en)
Japanese (ja)
Other versions
JP7587506B2 (ja
JP2022517407A (ja
Filing date
Publication date
Priority claimed from GBGB1900702.0A external-priority patent/GB201900702D0/en
Application filed filed Critical
Publication of JP2022517407A publication Critical patent/JP2022517407A/ja
Publication of JP2022517407A5 publication Critical patent/JP2022517407A5/ja
Priority to JP2024167091A priority Critical patent/JP7835461B2/ja
Application granted granted Critical
Publication of JP7587506B2 publication Critical patent/JP7587506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021541198A 2019-01-18 2020-01-17 ネフローゼ症候群を処置するためのaav遺伝子療法 Active JP7587506B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024167091A JP7835461B2 (ja) 2019-01-18 2024-09-26 ネフローゼ症候群を処置するためのaav遺伝子療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1900702.0A GB201900702D0 (en) 2019-01-18 2019-01-18 Therapy
GB1900702.0 2019-01-18
PCT/GB2020/050097 WO2020148548A1 (en) 2019-01-18 2020-01-17 Aav gene therapy for treating nephrotic syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024167091A Division JP7835461B2 (ja) 2019-01-18 2024-09-26 ネフローゼ症候群を処置するためのaav遺伝子療法

Publications (3)

Publication Number Publication Date
JP2022517407A JP2022517407A (ja) 2022-03-08
JP2022517407A5 true JP2022517407A5 (https=) 2023-01-30
JP7587506B2 JP7587506B2 (ja) 2024-11-20

Family

ID=65528327

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021541198A Active JP7587506B2 (ja) 2019-01-18 2020-01-17 ネフローゼ症候群を処置するためのaav遺伝子療法
JP2024167091A Active JP7835461B2 (ja) 2019-01-18 2024-09-26 ネフローゼ症候群を処置するためのaav遺伝子療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024167091A Active JP7835461B2 (ja) 2019-01-18 2024-09-26 ネフローゼ症候群を処置するためのaav遺伝子療法

Country Status (8)

Country Link
US (2) US12544460B2 (https=)
EP (2) EP3911368A1 (https=)
JP (2) JP7587506B2 (https=)
CN (2) CN120683181A (https=)
AU (2) AU2020208997B2 (https=)
CA (1) CA3126429A1 (https=)
GB (1) GB201900702D0 (https=)
WO (1) WO2020148548A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
GB202003109D0 (en) 2020-03-04 2020-04-15 Univ Bristol Gene therapy
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
GB202009039D0 (en) 2020-06-15 2020-07-29 Univ Bristol Therapy
GB202103470D0 (en) * 2021-03-12 2021-04-28 Univ Bristol Promoter
CN114592052A (zh) * 2022-04-01 2022-06-07 中国人民解放军陆军军医大学第二附属医院 一种肾病综合征患者pdss2致病突变基因及其检测试剂
EP4273243A1 (en) 2022-05-02 2023-11-08 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Nucleic acid constructs and vectors for podocyte specific expression
WO2025072667A2 (en) * 2023-09-29 2025-04-03 University Of Utah Research Foundation Compositions and methods for treating phosphomannomutase 2 (pmm2) deficiency
CN117871216B (zh) * 2024-03-12 2024-06-04 中日友好医院(中日友好临床医学研究所) 一种石蜡标本中肾小球裂隙膜的三维可视化方法
GB202414499D0 (en) * 2024-10-02 2024-11-13 Purespring Therapeutics Ltd Methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
FR2804127B1 (fr) 2000-01-20 2004-12-24 Inst Nat Sante Rech Med Gene srn1 implique dans le syndrome nephrotique cortico- resistant, proteine codee par ce gene et utilisations diagnostiques et therapeutiques
AU2003220966A1 (en) 2002-04-03 2003-10-13 Naohide Yamashita Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2007125723A1 (ja) 2006-04-28 2007-11-08 Osaka University 糸球体スリット蛋白誘導剤
CN105745326A (zh) * 2013-10-24 2016-07-06 优尼科Ip有限公司 用于基因治疗神经疾病的aav-5假型载体
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
HK1256681A1 (zh) 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
JP6978774B2 (ja) 2015-11-06 2021-12-08 国立大学法人 熊本大学 心不全の予防又は治療のための医薬組成物
WO2017144080A1 (en) 2016-02-23 2017-08-31 Eyeserv Gmbh Gene therapy for the treatment of a disease of retinal cone cells
CN109715205A (zh) 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
WO2018144709A2 (en) 2017-02-01 2018-08-09 The Trustees Of The University Of Pennsylvania Gene therapy for treating citrullenemia
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
EP4273243A1 (en) 2022-05-02 2023-11-08 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Nucleic acid constructs and vectors for podocyte specific expression

Similar Documents

Publication Publication Date Title
JP2022517407A5 (https=)
JP2022516283A5 (https=)
JP2018537984A5 (https=)
JP2020519292A5 (https=)
IE904292A1 (en) Pharmaceutical for subcutaneous administration containing polypeptides
JP2022505877A5 (https=)
JP2020527167A5 (https=)
Gruntman et al. Bridging from intramuscular to limb perfusion delivery of rAAV: optimization in a non-human primate study
JP2020526525A5 (https=)
JP2023020885A5 (https=)
JP2018534306A5 (https=)
Zhao et al. Acute cardiac herniation after left intrapericardial pneumonectomy
Sherman et al. Portal vein delivery of viral vectors for gene therapy for hemophilia
Suiter First and next generation native rFVIII in the treatment of hemophilia A. What has been achieved? Can patients be switched safely?
Tiuca et al. The news of treatment of variceal upper gastrointestinal bleeding
JP2023544409A5 (https=)
Harada et al. Use of bovine lung heparin to obviate anaphylactic shock caused by porcine gut heparin
JP2002522507A (ja) 疾患状態の処置
Tabata et al. Short arm deletion of chromosome 1: del (1)(p13. 3 p22. 3) in a female infant with an extreme tetralogy of Fallot
Jagirdhar et al. Decline of the Sengstaken-Blakemore tube: A review of shifting practices in gastrointestinal hemorrhage management
JP2022089867A (ja) 安定なイブプロフェン注射製剤用組成物
Bellot et al. Oral management in a patient with gardner-diamond syndrome: a case report
Im et al. Unusual causes of nasal septal abscess including a COVID-19 swab test after nasal surgery
Johnson et al. Gastric mucormycosis as a cause of life-threatening upper gastrointestinal bleeding in a trauma patient
Abbasi et al. Extracorporeal life support in adults with acute respiratory failure: current evidence-based practices